…
Ocean Sciences Ltd, together with its subsidiaries, engages in sourcing, producing, marketing, and selling traditional medicines in Australia, Singapore, China, and Southeast Asia. The company's products include raw bird's nest and processed bird's nest products, and Caulerpa Lentillifera, sea grapes, and seaweeds. Its products are used in the food, nutrition, healthcare, health supplements, cosmetics and personal care industries. Ocean Sciences Ltd was formerly known as BPH Global Ltd and changed its name to Ocean Sciences Ltd in September 2026. The company was incorporated in 1984 and is based in Melbourne, Australia.
Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website
A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.
Public information on BPH Global Ltd (ASX:BP8) is limited and does not clearly state its current operating business or strategy. As a small Australian-listed company, potential long-term growth would depend on clarified strategy, successful execution of any announced transactions or asset developments, and broader market conditions that may attract investors monitoring corporate updates.
Principal risks are limited public disclosure and transparency, low liquidity and higher volatility typical of small-cap ASX listings, plus execution and financing risk if the company pursues asset acquisitions or project development.
Note: The summary and risk score provided above is created by AI and should not be construed as a recommendation of Kalkine.
| Breakdown | 2026-06-30 | 2025-06-30 | 2024-06-30 | 2023-06-30 | 2022-06-30 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2026-06-30 | 2025-06-30 | 2024-06-30 | 2023-06-30 | 2022-06-30 |
| Income before tax | -1.66M | -1.49M | -1.78M | -3.54M | -2.79M |
| Minority interest | - | - | 0.18M | -0.22M | -0.75M |
| Net income | -1.79M | -1.49M | -2.27M | -4.32M | -2.86M |
| Selling general administrative | - | - | 0.98M | 1.76M | 3.13M |
| Selling and marketing expenses | - | - | 0.26M | - | 0.18M |
| Gross profit | -0.89M | -0.68M | 0.02M | 0.00M | 2.39M |
| Reconciled depreciation | - | - | - | 0.02M | 0.24M |
| Ebit | -1.77M | -1.45M | - | -2.54M | -2.73M |
| Ebitda | -1.76M | -1.45M | -1.76M | -2.35M | -2.49M |
| Depreciation and amortization | 0.01M | 0.00M | - | - | 0.24M |
| Operating income | -1.77M | -1.46M | -1.75M | -2.37M | -2.73M |
| Other operating expenses | 5.22M | 1.81M | 1.86M | 0.00M | 17.14M |
| Interest expense | 0.09M | 0.03M | 0.02M | - | 0.06M |
| Tax provision | - | - | 0.00M | 0.00M | 0.00M |
| Net interest income | - | - | -0.02M | - | -0.06M |
| Income tax expense | - | - | - | - | 0.06M |
| Total revenue | 3.44M | 0.35M | 0.11M | 0.00M | 14.34M |
| Total operating expenses | 0.88M | 0.78M | 1.77M | - | 5.19M |
| Cost of revenue | 4.33M | 1.03M | 0.09M | - | 11.95M |
| Total other income expense net | 0.11M | -0.03M | -0.02M | -1.17M | -0.06M |
| Discontinued operations | - | - | - | -0.57M | 1.62M |
| Net income from continuing ops | - | - | -1.78M | -3.54M | -2.79M |
| Net income applicable to common shares | - | - | - | -4.83M | -3.54M |
| Breakdown | 2026-06-30 | 2025-06-30 | 2024-06-30 | 2023-06-30 | 2022-06-30 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2026-06-30 | 2025-06-30 | 2024-06-30 | 2023-06-30 | 2022-06-30 |
| Total assets | 1.38M | 0.54M | 0.28M | 1.89M | 7.62M |
| Intangible assets | - | - | 0.00M | - | 0.00M |
| Other current assets | 0.27M | 0.04M | - | 0.00M | 0.25M |
| Total liab | 2.26M | 2.01M | 1.70M | 1.19M | 2.90M |
| Total stockholder equity | -0.87M | -1.45M | -1.41M | 0.53M | 3.04M |
| Other current liab | 1.44M | 1.67M | - | 0.55M | 1.64M |
| Common stock | 82.34M | 80.20M | - | 78.19M | 76.88M |
| Capital stock | - | - | 78.88M | 78.28M | 76.88M |
| Retained earnings | -85.08M | -83.45M | -82.20M | -81.31M | -77.97M |
| Other liab | - | - | - | - | -0.00M |
| Cash | 0.26M | 0.15M | 0.13M | 0.51M | 0.62M |
| Cash and equivalents | - | - | - | - | 0.62M |
| Total current liabilities | 2.26M | 2.01M | 1.70M | 1.28M | 2.81M |
| Net debt | 0.30M | -0.15M | 0.12M | - | 0.63M |
| Short term debt | 0.56M | - | - | - | 1.16M |
| Short long term debt | - | - | 0.25M | - | 1.09M |
| Short long term debt total | 0.56M | - | - | - | 1.25M |
| Other stockholder equity | - | - | - | 3.14M | -0.15M |
| Property plant equipment | - | - | - | 0.63M | 1.71M |
| Total current assets | 1.34M | 0.54M | 0.28M | 0.63M | 5.94M |
| Long term investments | - | - | - | - | 0.00M |
| Net tangible assets | - | - | - | 0.02M | 3.20M |
| Short term investments | - | - | 0.00M | 0.63M | 0.06M |
| Net receivables | 0.81M | 0.21M | - | 0.02M | 3.35M |
| Long term debt | - | - | - | - | 0.04M |
| Inventory | - | 0.14M | 0.05M | - | 1.32M |
| Accounts payable | 0.27M | 0.33M | 0.00M | 0.00M | 0.01M |
| Accumulated other comprehensive income | 1.88M | 1.80M | - | - | 4.29M |
| Non currrent assets other | - | - | - | - | -0.03M |
| Non current assets total | 0.04M | 0.00M | 0.00M | 0.63M | 1.69M |
| Capital lease obligations | - | - | - | - | 0.12M |
| Long term debt total | - | - | - | - | 0.09M |
| Breakdown | 2026-06-30 | 2025-06-30 | 2024-06-30 | 2023-06-30 | 2022-06-30 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2026-06-30 | 2025-06-30 | 2024-06-30 | 2023-06-30 | 2022-06-30 |
| Investments | - | - | 0.19M | 0.01M | -0.91M |
| Change to liabilities | - | - | - | 0.20M | -0.25M |
| Total cashflows from investing activities | -0.01M | -0.00M | 0.19M | -0.08M | -0.91M |
| Net borrowings | - | - | 0.38M | -0.11M | 0.28M |
| Total cash from financing activities | 2.44M | 0.96M | 0.70M | 1.38M | 0.28M |
| Change to operating activities | - | - | - | 0.68M | -0.18M |
| Net income | -1.66M | -1.49M | -2.27M | -4.83M | -2.86M |
| Change in cash | 0.11M | 0.02M | -0.38M | -0.11M | -4.63M |
| Begin period cash flow | 0.15M | 0.13M | 0.51M | 0.62M | 5.26M |
| End period cash flow | 0.26M | 0.15M | 0.13M | 0.51M | 0.62M |
| Total cash from operating activities | -2.14M | -0.93M | - | -1.34M | -2.62M |
| Issuance of capital stock | - | - | 0.32M | 1.49M | - |
| Depreciation | 0.01M | 0.00M | - | 0.12M | 0.24M |
| Other cashflows from investing activities | 0.01M | - | - | - | 0.00M |
| Change to inventory | - | -0.09M | - | -0.13M | -0.61M |
| Change to account receivables | - | -0.11M | - | -0.49M | -1.54M |
| Sale purchase of stock | - | - | - | - | 0.00M |
| Other cashflows from financing activities | -0.03M | - | - | - | 1.07M |
| Change to netincome | - | - | - | 3.10M | -0.72M |
| Capital expenditures | 0.01M | 0.00M | 0.00M | 0.15M | 0.91M |
| Change in working capital | - | 0.42M | - | - | 0.02M |
| Other non cash items | -0.49M | 0.14M | - | - | 2.62M |
| Free cash flow | -2.14M | -0.93M | -1.26M | -1.49M | -3.53M |
|
Stock Name
|
Change
(AUD) |
Price
(AUD) |
Trailing
PE (x) |
Forward
PE (x) |
Price Sales
TTM (x) |
Price to Book Value (x)
|
Enterprise Value
to Revenue (x) |
Enterprise Value
to EBITDA (x) |
|---|---|---|---|---|---|---|---|---|
| CBAPI Commonwealth Bank of Australia |
0.02 0.02% |
101.50 | - | - | - | - | - | - |
| RF1 Regal Investment Fund |
-0.07 2.30% |
2.98 | - | - | - | - | - | - |
| PCI Perpetual Credit Income Trust |
0.01 0.46% |
1.08 | - | - | - | - | - | - |
| HGO Hillgrove Resources Ltd |
0.04 4.21% |
1.11 | 0.90 | 3.21 | 1.28 | 2.00 | 1.08 | 4.56 |
Ocean Sciences Ltd, together with its subsidiaries, engages in sourcing, producing, marketing, and selling traditional medicines in Australia, Singapore, China, and Southeast Asia. The company's products include raw bird's nest and processed bird's nest products, and Caulerpa Lentillifera, sea grapes, and seaweeds. Its products are used in the food, nutrition, healthcare, health supplements, cosmetics and personal care industries. Ocean Sciences Ltd was formerly known as BPH Global Ltd and changed its name to Ocean Sciences Ltd in September 2026. The company was incorporated in 1984 and is based in Melbourne, Australia.
| Name | Title | Year Born |
|---|---|---|
| Mr. Huan Qing Gu | CEO, MD & Director | NA |
| Mr. Chow-Yee Koh | CFO & Director | 1976 |
| Ms. Elizabeth Spooner | Joint Company Sec. | NA |
| Ms. Belinda Cleminson | Joint Company Sec. | NA |
| Mr. Francesco Cannavo | Part-Time Executive Director | NA |
| Mr. Matthew Leonard | MD & Executive Director | NA |
| Mr. Chow-Yee Koh | Chief Financial Officer | 1976 |
| Mr. Francesco Cannavo | Part-Time Executive Director | NA |
| Ms. Belinda Cleminson | Joint Company Secretary | NA |
| Ms. Shelby Coleman | Joint Company Secretary | NA |
Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.